![Ziarco Logo](/news-release/logo/317396/0/317396.png?lastModified=12%2F10%2F2016%2011%3A47%3A59&size=2)
Ziarco Appoints Mike Grey as Executive Chairman of Board of Directors
July 20, 2015 08:00 ET
|
Ziarco Group Ltd.
CANTERBURY, United Kingdom, July 20, 2015 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Mike Grey as...
![Ziarco Logo](/news-release/logo/317396/0/317396.png?lastModified=12%2F10%2F2016%2011%3A47%3A59&size=2)
Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
June 10, 2015 08:00 ET
|
Ziarco Group Ltd.
CANTERBURY, England, June 10, 2015 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced that it has dosed the first patient in its...
![Ziarco Logo](/news-release/logo/317396/0/317396.png?lastModified=12%2F10%2F2016%2011%3A47%3A59&size=2)
Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
June 08, 2015 08:00 ET
|
Ziarco Group Ltd.
CANTERBURY, UK, June 8, 2015 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Pablo Jimenez,...
![Ziarco Logo](/news-release/logo/317396/0/317396.png?lastModified=12%2F10%2F2016%2011%3A47%3A59&size=2)
Ziarco Announces Appointment of Mike Grey to Board of Directors
December 01, 2014 08:00 ET
|
Ziarco Group Ltd.
CANTERBURY, UK, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the addition of Mike Grey to its Board of...
![Ziarco Logo](/news-release/logo/317396/0/317396.png?lastModified=12%2F10%2F2016%2011%3A47%3A59&size=2)
Ziarco Raises $33.1 Million in Series B Financing
November 10, 2014 07:00 ET
|
Ziarco Group Ltd.
CANTERBURY, England, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B...